Awaiting development: Guidance and quality standards

Showing 1 to 9 of 9

Guidance and quality standards awaiting development
Title	Type
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Bimekizumab for treating ankylosing spondylitis [ID4011]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]	Technology appraisal guidance
Sabizabulin for treating COVID 19 [TSID11814]	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]	Technology appraisal guidance
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance